| 產(chǎn)品名稱 | TAK 259 |
| 產(chǎn)品貨號(hào) | Axon 2579 CAS [1192347-42-4] MF C14H13Cl2N3O3S.HClMW 410.70 Purity: 99% Soluble in water and DMSO Description Novel, selective, and orally active α1D adrenoceptor antagonist (Ki value 1.1 nM, and 200-800 fold selective over α1A and α1B, respectively) with anti-urinary frequency effects: reducing human Ether-a-go-go-Related Gene (hERG) liabilities. Clinical candidate, and a promising novel therapeutic agent for the treatment of OAB (overactive bladder) symptoms. KEYWORDS:?TAK 259 | supplier | α1D antagonist | TAK259 | CAS [1192347-42-4] | [1192348-73-4] | Adrenaline | Adrenoceptor α1 | GPCR | anti-urinary | hERG liabilities | human Ether-a-go-go-Related Gene | overactive bladder | OAB |
| 產(chǎn)品價(jià)格 | 現(xiàn)貨詢價(jià)，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
TAK 259Axon 2579 CAS [1192347-42-4] MF C14H13Cl2N3O3S.HCl
DescriptionNovel, selective, and orally active α1D adrenoceptor antagonist (Ki value 1.1 nM, and 200-800 fold selective over α1A and α1B, respectively) with anti-urinary frequency effects: reducing human Ether-a-go-go-Related Gene (hERG) liabilities. Clinical candidate, and a promising novel therapeutic agent for the treatment of OAB (overactive bladder) symptoms. KEYWORDS:?TAK 259 | supplier | α1D antagonist | TAK259 | CAS [1192347-42-4] | [1192348-73-4] | Adrenaline | Adrenoceptor α1 | GPCR | anti-urinary | hERG liabilities | human Ether-a-go-go-Related Gene | overactive bladder | OAB
Selective and orally active α1D adrenoceptor antagonist
Chemical name5-chloro-1-(5-chloro-2-(methylsulfonyl)benzyl)-2-imino-1,2-dihydropyridine-3-carboxamide hydrochloride Parent CAS No.[1192348-73-4] |
| 產(chǎn)品資料 |
